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309 Piloting the use of the cystic ﬁbrosis questionnaire (CFQ) in CF
patients changing to dry powder inhaled colistimethate
S.P. Conway1, J.C. Davies2, C. Etherington1, M.H. Goldman3, E. Howard3,
A. Jaffe4, N.K. Lard3. 1Seacroft Hospital, Leeds, United Kingdom; 2Royal
Brompton Hospital, London, United Kingdom; 3Forest Laboratories UK Ltd,
Bexley, United Kingdom; 4Great Ormond Street Hospital, London, United
Kingdom
As part of a phase II multi-dose tolerability study of dry powder inhaled colis-
timethate (DPIC), the planned phase III secondary endpoint of CFQ was piloted.
16 CF patients aged 8 and over were studied in an open-label, cross-over study
to compare treatment with 2MU nebulised colistimethate (NC)BID and 125mg of
DPIC BID. The duration of each treatment was 28 days.
An English version of the CFQ was administered at the beginning and end of
the treatment phases. At the end of each treatment arm the CFQ responses were
analysed.
The results conﬁrmed there was a statistically signiﬁcant (p = 0.007, mean
difference-4.3, SD 3.17) improvement in the CFQ of these patients, after 28 days
of DPIC 125mg BID. There was a statistically non-signiﬁcant (p = 0.15, mean
difference −1.9, SD 3.4) improvement in the CFQ of these patients after 28 days of
NC 2MU BID. From the Parent/Caregiver responses it was identiﬁed that parents
saw improvement (p = 0.44, mean difference −1.6, SD 3.17) in their children’s CFQ
in the following domains; physical, vitality, body, school, respiratory and digestion,
after DPIC. The improvement seen by parents in their children after treatment with
28 days of NC was also statistically non-signiﬁcant (p = 0.5, mean difference −1.3,
SD 5.6).
It was concluded that the CFQ is a practical instrument to use in clinical trials.
Although the piloted versions of the CFQ seemed relevant, the instrument seemed
unsuitable for use in such a small study as variability (measured by 95% CI and
SD) is marked. Short study duration may also obscure changes in CFQ.
Supported by: Forest Laboratories UK Ltd.
310 Development of a unidimentional health status measure for
cystic ﬁbrosis (CF)
S.F. Scott1, S. Spencer2, M. Meguro2, M.E. Hodson1, P.W. Jones2. 1Cystic
Fibrosis, Royal Brompton Hospital, London, United Kingdom; 2St. George’s
University of London, London, United Kingdom
Aim: To create an item pool and select items using classical test theory (CTT) and
item response theory (IRT) to develop a health status (HS) questionnaire for adults
with CF.
Methods: Following a literature review, consultation with CF specialists and semi-
structured patient interviews, an item pool consisting of 178 items was created.
Items were tested and shown to have a good level of comprehension and clarity.
They were grouped into domains and administered to 205 patients together with
two global scales that assess global health (GQoL) and overall chest score (GCS).
Responses to items were scored as “yes”, “no” and “not applicable”. One week
later, a subset of 54 patients was given the same items. Items that were removed if
they had gender or age biases, weak association with GQoL and GCS, a response
rate <10% or >90%, not applicable rate >20% and poor repeatability. Remaining
items were subjected to IRT to test their ﬁt to a unidimensional model. Misﬁtting
items with ﬁt residual >±2.5 and signiﬁcant c2 were removed.
Results: The mean age of the group was 28.6 years (17−64 years) with a mean
FEV1 48.4 (11.9–116.3)% predicted. One hundred and twenty nine items met
the CTT exclusion criteria and the 11 misﬁtting items identiﬁed by IRT were
removed. The overall item ﬁt of the remaining 38 items to the unidimensional model
was good: mean item ﬁt residual −0.26, SD 1.5 and discriminatory function was
excellent (Person Separation Index 0.92). The intra-class correlation for repeatability
was 0.93.
Conclusions: Thirty-eight items were selected from the initial item pool to form
the CF-38 HS measure. It has very good measurement properties, is short, simple,
quick to use and score.
311 Validity and responsiveness of CF-38 health status measure
S.F. Scott1, M. Roughton2, P.W. Jones3, M.E. Hodson1. 1Cystic Fibrosis, Royal
Brompton Hospital, London, United Kingdom; 2Medical Statistician, Royal
Brompton Hospital, London, United Kingdom; 3St. George’s University of London,
London, United Kingdom
Aims: To assess the validity and responsiveness of the CF-38, a newly developed
38-item health status measure for use in clinical trials and audit in adults with cystic
ﬁbrosis (CF).
Methods: Baseline data were collected in 204 patients (94 men) using CF-38,
CFQoL, SF-36 and two visual analogue scales (VAS) for use in routine care: global
health (GQoL) and global chest condition (GCS). Paired data were also collected
from 36 patients before and after effective treatment for an infective exacerbation.
Validity was tested using linear regression to examine the relationship between
CF-38 and related variables. Responsiveness was evaluated by examining changes
following treatment using the effect size (ES), which is the mean change divided by
the standard deviation of the differences in scores between patients pre-treatment.
Results: The age range of the patients was 17−67 years, their mean FEV1 was 50%
predicted. The CF-38 score correlated well with CFQoL at baseline (r = 0.86) and
moderately with FEV1 (r = 0.38), SF-36 and global scores (r in the range 0.53−0.66),
all p = 0.0001. In the patients who were treated for an exacerbation, the ES for the
CF-38 was 0.66 (large effect), FEV1 0.46 (medium effect) and GQoL VAS 1.63
(large effect).
Conclusions: The CF-38 demonstrated good validity and sensitivity to change
following treatment. It is more sensitive than FEV1 at quantifying change, but
less sensitive than the GQoL VAS. By contrast with the latter, the CF-38 is a
standardized instrument of known content and psychometric properties.
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A research tool is needed to estimate the time and effort involved in caring for a
child with CF for use as an outcome measure in clinical trials of new interventions.
Objective: To develop an instrument for estimating tangible burden associated with
caring for a child with CF aged up to 13 years.
Methods: The instrument was developed using qualitative methods (focus groups,
action research, in-depth interviews) with participating parents and a working group
of CF team professional staff. The pilot phase involved (i) cognitive interviewing
with n = 10 caregivers; and, (ii) formal validation with n = 30 caregivers completing
the questionnaire.
Results: The CFLC-Q takes 15 minutes to complete. The questionnaire structure
covers each aspect of CF care systematically: demographic characteristics, family
context, child’s character, CF history, challenge to family life, CF routines, local
medical service and supplies, hospital-based care, pharmacy as well as the time
and effort involved in treatments and routines. Face validity and acceptability are
established. Pilot data suggest this is a reliable, valid and useful tool.
Conclusions: Parents involved in the instrument construction saw its value not
only as a research tool but also a clinical tool at the annual review of their child’s
condition. Main validation is planned with a sample of n = 400 and will be designed
to exploit the measure’s full potential.
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